



---

## **ASX Announcement and Media Release**

**Thursday 2 October 2014**

**SciGen Ltd**

### **TRANSACTION FOR SALE OF 50.01% OF SCIGEN'S INTEREST IN SCIGEN BIOPHARMA PVT LTD.**

The Board of Directors of SciGen Limited (ASX:SIE) ("**SciGen**") announce that as of today, all Conditions Precedent to the Agreement with Anglo Gulf FZE ("**Anglo**") have been satisfied. In accordance to the Agreement, the parties undertake to perform the Transaction Closing within 10 business days after the day on which all the Conditions Precedent have been satisfied. Under the Agreement, SciGen sold its 50.01% interest in SciGen BioPharma Pvt Ltd ("**SBPL**") to Anglo Gulf FZE ("**Anglo**") or its nominee, for a cash consideration of US\$7,000,000. The transaction was approved by SciGen's shareholders at an Extraordinary General Meeting held on 21 August 2014.

#### **About SciGen**

SciGen Ltd is a progressive biopharmaceutical company involved in co-developing and marketing genetically engineered biopharmaceutical products for human healthcare. SciGen focuses in the areas of gastroenterology, endocrinology and immunology. Its product portfolio includes therapeutics such as rhuman Growth Hormone, rhuman Insulin and GCSF.

SciGen has acquired the rights to manufacture, distribute and market biopharmaceutical products under exclusive licensing arrangements. SciGen's portfolio currently includes proprietary biotechnology-derived products, and biosimilar products, which allows for faster entry into the market, as the biogeneric products have undergone much of the clinical development and trials required to bring new drugs to market. This minimises the risks associated with early stage product development.

SciGen currently undertakes R&D activities in collaboration with strategic partners and institutions.

SciGen's major strength lies in its ability to recognise the potential of new products in their early stages of development. Through joint collaboration with its strategic partners, SciGen uses its extensive expertise in regulatory and clinical environments, in conjunction with

marketing and promotional infrastructure, to bring to market products which will have significant long-term benefit.

SciGen's business was established in 1988. SciGen is a Singapore biotechnology company, publicly listed on the Australian Stock Exchange (ASX code SIE). SciGen's headquarters is in Singapore and it also has subsidiary companies and offices in Australia, South Korea, China, India and Philippines, distribution channels in China, India, Malaysia, Myanmar, Pakistan, Thailand and Indonesia and a contract manufacturer in Poland, Bioton S.A.

| <b>For further information:</b> Company - Investor Relations   | Company  |
|--|--|
| Ms. Gillian Dunlop<br>SciGen (Australia) Pty Ltd<br>+61 2 9485 1800<br>Email: <a href="mailto:gdunlop@scigen.com.au">gdunlop@scigen.com.au</a> | Slawomir Ziegert<br>CEO<br>SciGen Ltd<br>+65 6779 6638 |